Belzutifan/Lenvatinib Superior to Cabozantinib in Advanced RCC After PD-1 Failure

For patients battling advanced renal cell carcinoma (RCC) whose disease has progressed after initial immunotherapy, a recent combination therapy is showing promise. Recent data suggest that belzutifan, paired with lenvatinib, significantly improves outcomes compared to using cabozantinib alone. This finding offers a potential second-line treatment option for a challenging patient population, where options have been limited.

Understanding Advanced RCC and Treatment Challenges

Renal cell carcinoma, or kidney cancer, is a disease that often presents at an advanced stage, making treatment more complex. Immunotherapy – drugs that help the body’s own immune system fight cancer – has become a standard first-line treatment. However, a significant number of patients experience disease progression even with these therapies. Currently, cabozantinib, a tyrosine kinase inhibitor (TKI), is frequently used as a next step. TKIs function by blocking signals that tell cancer cells to grow and spread. But, as Dr. Robert J. Motzer of Memorial Sloan Kettering Cancer Center has noted, there’s been a relative lack of robust evidence demonstrating one drug is definitively better than another when immunotherapy fails. This is the gap the LITESPARK-011 trial aims to address.

LITESPARK-011: A Closer Look at the Trial Findings

The phase III LITESPARK-011 trial, presented at the 2026 ASCO Genitourinary Cancers Symposium, randomly assigned 747 patients with advanced clear cell RCC to either receive belzutifan plus lenvatinib (371 patients) or cabozantinib alone (376 patients). All participants had experienced disease progression following anti-PD-(L)1 therapy – a type of immunotherapy. The study’s primary goals were to assess progression-free survival (how long patients live without their cancer worsening) and overall survival. Objective response rate – the percentage of patients whose tumors shrink or disappear – was a key secondary endpoint. ASCO Post provides a detailed overview of the trial design.

The second interim analysis of the trial revealed that the combination of belzutifan and lenvatinib led to improved progression-free survival and a higher objective response rate compared to cabozantinib. There was too a trend toward improved overall survival, though further follow-up is needed to confirm this finding. Belzutifan is a first-in-class HIF-2α inhibitor. HIF-2α is a protein that helps cancer cells adapt to low oxygen levels, a common characteristic of tumors. By inhibiting HIF-2α, belzutifan can disrupt tumor growth. Lenvatinib, like cabozantinib, is a multitarget TKI, meaning it blocks multiple signaling pathways involved in cancer development. Medscape highlights the significance of these findings.

How Belzutifan and Lenvatinib Work Together

The rationale behind combining belzutifan and lenvatinib lies in their complementary mechanisms of action. Lenvatinib targets the vascular endothelial growth factor receptor (VEGFR), inhibiting the formation of new blood vessels that feed the tumor. Belzutifan, by targeting HIF-2α, addresses tumor growth in a different way. Dr. Motzer suggests that this dual approach – targeting tumor blood vessel growth through different pathways – may be more effective than using a VEGFR TKI alone. This strategy aims to overcome potential resistance mechanisms and maximize the therapeutic benefit.

What Does This Mean for Patients?

These findings offer a potential new treatment option for patients with advanced RCC who have exhausted other therapies. Currently, the standard of care after progression on immunotherapy is often a single TKI like cabozantinib. The LITESPARK-011 trial suggests that the belzutifan-lenvatinib combination could offer improved outcomes in this setting. However, it’s crucial to remember that this is an interim analysis and longer-term follow-up is needed to fully assess the benefits and risks of this combination.

Belzutifan itself received FDA approval in 2023, but for patients who were heavily pretreated. This trial expands the potential benefit to a broader group – those progressing after initial immunotherapy. It’s important to note that this research focuses specifically on patients with clear cell RCC, the most common type of kidney cancer. The applicability of these findings to other subtypes of RCC remains unclear.

Study Limitations and Future Directions

As with any clinical trial, LITESPARK-011 has limitations. The results presented are from an interim analysis, meaning the data are not yet fully mature. Longer follow-up is necessary to determine the long-term impact of the belzutifan-lenvatinib combination on overall survival. The trial enrolled patients who had received up to two prior systemic therapies, which may limit the generalizability of the findings to patients with different treatment histories. Urology Times provides further context on the trial’s methodology.

Looking ahead, continued monitoring of the LITESPARK-011 trial participants is essential. Researchers will be closely watching for any long-term side effects and to confirm the observed survival benefits. Further research may also explore biomarkers that could help identify patients who are most likely to respond to the belzutifan-lenvatinib combination. This personalized approach could optimize treatment decisions and improve outcomes for individuals with advanced RCC.

Next Steps in Clinical Practice

The findings from LITESPARK-011 are likely to prompt discussions among oncologists regarding the potential role of belzutifan-lenvatinib in the treatment of advanced RCC. Although not yet a standard of care, the data suggest it could become a viable second-line option. Patients should discuss their individual circumstances and treatment options with their healthcare team to determine the most appropriate course of action. Ongoing clinical trials will continue to refine our understanding of this combination therapy and its place in the evolving landscape of RCC treatment.